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Abstract 
Objectives 
To confirm whether 7-days phenytoin, an enzyme inducer, decreases the elimination half-
life of single-dose nevirapine and to investigate its effect on nevirapine resistance 
development in pregnant, HIV-infected women. 
 
Methods 
In a pharmacokinetic pilot trial(NCT01187719), Zambian/Tanzanian HIV-infected, 
antiretroviral (ARV)-naive pregnant women ≥18 years with CD4 >350 cells/mm3 were 
randomized 1:1 to control (zidovudine pre-delivery, single-dose 
nevirapine/zidovudine/lamivudine at delivery, zidovudine/lamivudine for 7 days post-
delivery) or intervention (control plus 184mg phenytoin once-daily for 7 days post-delivery) 
groups. Primary endpoints were nevirapine pharmacokinetics and resistance. 
Results 
35/37 women were allocated to control/intervention groups with median (IQR) age of 27 
(23-31) and 27 (23-33) years, respectively. 23/23 had detectable nevirapine levels at 
delivery and subsequent samples in control/intervention groups, respectively. Geometric 
mean (95%CI) nevirapine plasma levels at delivery were 1.02 (0.58-1.78) mg/L and 1.14 
(0.70-1.86) mg/L in control/intervention groups (p=0.76). One week after delivery, 0/23 
(0%) and 15/22 (68%) control/intervention mothers had undetectable levels (<0.05 mg/L; 
p<0.001). One week later, this was 10/21 (48%) and 18/19 (95%), respectively (p=0.002). 
GM(95%CI) nevirapine half-lives were 63.2 (52.8-75.7) versus 25.5 (21.6-30.1) hours in 
control versus intervention groups (p<0.001). New nevirapine mutations were found in 
0/20 (0%) intervention vs. 1/21 (5%) control mothers. There was no difference in adverse 
events (p>0.28). 
 
Conclusions 
Adding 7-days of an enzyme inducer to single-dose nevirapine to prevent mother-to-child 
transmission significantly reduced subtherapeutic nevirapine levels by shortening 
nevirapine half-life. As prolonged subtherapeutic nevirapine leads to resistance 
emergence, a single-dose nevirapine could be used with phenytoin as an alternative if 
other ARVs are unavailable. 
 
Introduction 
While the risk of HIV mother-to-child transmission (MTCT) is 20-40% without treatment,1, 2 a 
simple cheap intervention, single-dose nevirapine at labour onset, reduces MTCT by ~50%.1, 
3 Its major disadvantage is development of nevirapine resistance in mothers (1-69%) and 
infants,4 most likely due to its long elimination half-life (61 hours),5 leading to several days to 
weeks of subtherapeutic plasma concentrations, coupled with its low genetic barrier to 
resistance6. Newly emergent  
 
Page 2610 --> 
 
resistant HIV may be transmitted to the infant or to others, limiting their treatment options, 
and may also reduce future combination antiretroviral therapy (cART) efficacy in the mother.7  
 
Given its simplicity and efficacy, single-dose nevirapine is nevertheless still endorsed by the 
WHO as part of the regimen for preventing MTCT (pMTCT) in resource-limited settings, 
when cART (WHO Option B/B+) is not feasible or available. To cover the prolonged presence 
of subtherapeutic nevirapine plasma concentrations after single-dose nevirapine at labour 
onset, Option A of the WHO (2012) guidelines recommend adding zidovudine/lamivudine for 
seven days postpartum.8, 9 This approach reduces resistance development to 4-16%,4 but 
does not fully eliminate it. 
 
Nevirapine is extensively metabolized in the liver by cytochrome P450 (CYP) isoenzymes 
3A4 and 2B6.10 A pharmacological, rather than antiretroviral, approach of adding a CYP3A4 
enzyme inducer has been shown to decrease nevirapine elimination half-life in healthy 
women,11 with greatest reductions from carbamazepine and phenytoin. In our previous trial 
(VITA-1), addition of single-dose carbamazepine to single-dose nevirapine at labour onset 
also significantly reduced nevirapine plasma concentrations one week after delivery in HIV-
infected women, with a trend towards fewer resistance mutations.12 
 
The CYP3A4 enzyme inducer phenytoin is a low cost, widely available anticonvulsant and 
anti-arrhythmic drug, which is not secreted into breast milk in clinically important amounts  (in 
contrast to carbamazepine) and can therefore be safely given to breastfeeding mothers.13 In 
this pilot study we investigated the impact of seven days phenytoin on nevirapine 
pharmacokinetics and nevirapine resistance development after single-dose nevirapine as a 
component of antiretroviral (ARV) prophylaxis for pMTCT (VITA-2 trial). 
 
Methods 
 
Study participants 
Participants were recruited from the Pasua and Majengo antenatal clinics (ANCs) in Moshi, 
Tanzania and University Teaching Hospital (UTH) in Lusaka, Zambia. Eligible, HIV-infected, 
pregnant women were aged ≥18 years, ARV-naive, starting ARV prophylaxis for pMTCT, not 
intending to relocate during study participation, and willing to attend follow-up visits. 
Exclusion criteria were serious illness requiring systemic treatment/hospitalization, use of 
concomitant medication which may interfere with ARVs or phenytoin, or CD4 <350 cells/mm3 
(eligible for cART). All women gave written informed consent; illiterate patients gave oral 
consent documented by their own thumbprint and a witness. The study was approved by 
institutional review boards of Kilimanjaro Christian Medical University College (KCMU-Co), 
Moshi, Tanzania, the National Institute of Medical Research in Dar es Salaam, Tanzania, and 
UTH, Lusaka, Zambia. The study is registered with ClinicalTrials.gov (NCT01187719). 
 
Eligible women all received pMTCT ARV prophylaxis recommended by national 
Tanzanian/Zambian guidelines. Subjects started zidovudine 300mg twice daily from 28/14 
weeks of gestation in Tanzania/Zambia, respectively, or as soon as possible thereafter pre-
delivery. At labour onset, women received 200mg single-dose nevirapine plus oral 300mg 
zidovudine  every three hours and lamivudine 150mg every 12 hours until delivery (Tanzania) 
or oral zidovudine 600mg and lamivudine 300mg every 12 hours until delivery (Zambia). 
Post-delivery zidovudine 300mg and lamivudine 150mg was taken twice daily for seven days. 
Newborns were given 2mg/kg single-dose nevirapine suspension within 24-72 hours after 
birth then zidovudine syrup 4mg/kg (Tanzania) or nevirapine suspension 2mg/kg (Zambia) 
twice daily for seven days. All women in the trial breastfed their children for six months and 
then weaned rapidly. 
 
Women were randomized 1:1 to either the national standard of care or the national standard 
of care plus 184mg phenytoin (2x92mg tablets) once daily from labour onset for seven days. 
Participant codes and allocations were held in secure envelopes stored by the project 
manager at each site. At enrolment (pre-delivery), women were randomized by the study 
doctor at the clinic opening the next envelope. When the woman presented in labour at the 
clinic, a study nurse confirmed and recorded time of study drug(s) ingestion by direct 
observation of intake or by asking the woman if she had already taken the study drug(s) at 
home.  
 
Objectives, outcomes and follow-up 
The primary objectives of the pilot study were to determine the effect of seven days 
phenytoin on the elimination half-life of nevirapine and the development of nevirapine 
resistance in HIV-infected pregnant women receiving a single-dose nevirapine as part of 
perinatal HIV prevention. The primary outcomes were nevirapine pharmacokinetic 
parameters (elimination half-life, time to achieve an undetectable plasma concentration) and 
nevirapine resistance (primary nevirapine mutations L100I, K101P, K103N/S, V106A/M, 
V108I, Y181C/I, Y188C/L/H, G190A)14 at weeks 4-6. Secondary outcomes were all adverse 
events (AEs) possibly/probably related to pMTCT ARV prophylaxis or phenytoin, and HIV 
infection of the infant. 
 
Haematology and biochemistry tests were performed at enrolment and one week post-
partum. CD4 cell counts and viral load (VL) were assayed at delivery. Infants were tested just 
after birth (<30 minutes) and at week 4-6 by DNA PCR assays. Blood was stored from the 
women at delivery and days 1,3,5,7 and 14 postpartum, and from the children at delivery and 
day 7 post-delivery for retrospective determination of nevirapine (and phenytoin) plasma 
concentrations at the Department of Pharmacy, Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands. Nevirapine assay used high performance liquid 
chromatography with a lower limit of quantification (LLOQ) of 0.05 mg/L 15 and phenytoin was 
determined by a validated immunoassay with an LLOQ of 0.4 mg/L. Nevirapine resistance 
was assayed in plasma stored from samples at baseline and week 4/6 at the Department of 
Virology of the University Medical Centre Utrecht, The Netherlands.  
 
The sample size of 50 subjects (25 per arm) delivering in the study clinic provided >80% 
power to detect a decrease of at least 27% in nevirapine elimination half-life associated with 
seven days phenytoin allowing 20% drop-out (without follow-up samples, based on VITA-1).12  
 
Safety analyses included all women who were observed or reported taking study medication 
(safety population). Analyses of pharmacokinetics and resistance included the safety 
population who did not receive a second nevirapine dose, who delivered vaginally (not by 
caesarean section (C/S)) and had pharmacokinetic evidence of nevirapine, and phenytoin if 
allocated (detectable plasma concentration one day post-delivery) (protocol-specified primary 
PK population). Analyses were also done including mothers who delivered by C/S, as no 
difference in pharmacokinetic parameters was observed between C/S and vaginal deliveries 
in VITA-1. Women in the control group with phenytoin detected in any sample were excluded 
from PK/resistance analyses. Pharmacokinetic analysis was performed using Phoenix 64, 
WinNonlin 6.3 (Pharsight  
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Corporation, CA, USA) and statistical analysis using SPSS, version 18.0 (SPSS Inc.). 
 
Results 
 
Study participants 
We screened 335 HIV-infected, pregnant women from July 2010 to June 2011; most of the 
262 women not randomized were already on cART (n=94), had CD4 <350 cells/mm3 (n=82) 
or did not return after screening (n=56) (Figure 1). Seventy-three (22%) women were 
randomized: 35 and 37 were allocated to control and intervention groups, respectively. One 
woman was randomized twice; the second randomization was excluded and the woman 
followed the first randomization. Demographic characteristics at enrolment and delivery were 
generally reasonably balanced between the two groups (Table 1; Supplementary Table 1); 
the main difference was significantly shorter time from nevirapine ingestion to delivery in the 
intervention group, which must  
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have occurred by chance. The difference is not expected to have impact on our 
pharmacokinetic data, as the elimination half-life of nevirapine is long. Also, no differences 
were observed between laboratory values at enrolment and delivery within either group 
(Supplementary Table 1). 
 
Pharmacokinetics 
At delivery, restricting to women who delivered vaginally (not by C/S), there was no 
significant difference in nevirapine plasma concentrations in the two groups (geometric mean 
(GM) (95%CI) was 1.08 (0.63-1.84) mg/L in control patients versus 1.14 (0.70-1.86) mg/L in 
intervention patients, GM ratio (GMR) (90%CI) 1.05 (0.58-1.92), t-test p=0.82). Subsequently 
nevirapine plasma concentrations decreased significantly faster (Figure 2) and undetectable 
levels were reached significantly earlier (Table 2) in the intervention group compared to the 
control group. All results were similar including women who delivered by C/S, and so those 
from the (larger) group including women who delivered by C/S are presented subsequently 
(see Supplementary Table 2 for pharmacokinetic results of the (smaller) group excluding 
women who delivered by C/S). 
 
One week post-delivery, nevirapine plasma concentrations were reduced in both groups, but 
to a significantly lesser extent in the control group (GMR (1-week:delivery) (90%CI) 0.22 
(0.18-0.28), 20 matched pairs) than the intervention group (GMR (1-week:delivery) (90%CI) 
0.031 (0.026-0.038), 22 matched pairs). Overall, levels were 85% lower in intervention than 
control groups (GMR (intervention:control) (90%CI) 0.15 (0.11-0.20), t-test p<0.001). The GM 
(95%CI) nevirapine elimination half-life was 63.2 (52.8-75.7) versus 25.5 (21.6-30.1) hours in 
the control versus intervention groups respectively (p<0.001; t-test), a 60% reduction (GMR 
(90%CI) 0.40 (0.33-0.49)). The GM (95%CI) time to achieving an undetectable nevirapine 
plasma concentration was 16.3 (13.8-19.3) versus 6.7 (5.7-7.8) days in the control versus 
intervention groups respectively (p<0.001; t-test). Consequently a significantly greater 
proportion of control women had detectable nevirapine plasma levels at one and two weeks 
post-delivery (Table 2). All 23 (100%) women in the control group versus 7/22 (32%) women 
in the intervention group had a detectable nevirapine plasma concentration at one week post-
delivery (p<0.001; exact); and 11/21 (52%) women in the control group versus 1/19 (5%) 
women in the intervention group at two weeks post-delivery (p=0.002; exact). 
 
The median (range) phenytoin plasma concentration in all samples taken from delivery to 
one week post-delivery in the intervention group was 1.5 (<0.4-24.7) mg/L. Twenty-one of 22 
(95%) mothers had only subtherapeutic phenytoin levels (therapeutic range defined as 10-20 
mg/L).16 One (5%) mother had an undetectable plasma concentration at delivery, but her 
plasma level was detectable on day 1 and increased to 24.7 mg/L one week post-delivery. 
The median phenytoin plasma level in the infants was <0.4 (range <0.4-1.9 mg/L). 
 
Resistance 
Samples 4-6 weeks post-delivery were available from 21 control women (1 missed week 6 
visit; for 1  
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sample amplification failed due to low VL) and 20 intervention women (3 missed week 4/6 
visit). One (5%) of the 21 women in the control group had one nevirapine-associated 
resistance mutation (elimination half-life 123.5 hours), which was not present at baseline, 
versus 1/20 (5%) with one nevirapine-associated resistance mutation in the intervention 
group. However, the mutation in the patient from the intervention group was already present 
in a sample stored at delivery. Both mutations were detected as mixtures with wild-type 
nucleotide sequence (V106MV control; K103KN intervention). 
 
Safety 
The 28 control and 26 intervention mothers gave birth to 30 (two pairs of twins) and 28 
babies (two pairs of twins), respectively. Twenty-one (one pair of twins) and 19 (one pair of 
twins) infants respectively were tested just after birth and at weeks 4-6 post-delivery. The 
overall transmission rate was 0/21 (0%) in the control group and 1/19 (5%) in the intervention 
group. However, the infected child tested positive at birth and must therefore have been 
infected during the intrauterine period. In the infants, ten clinical AEs were reported: four in 
the control group (n=1 grade 1, n=1 grade 2, n=2 grade 4) and six in the intervention group 
(n=1 grade 1, n=1 grade 2, n=1 grade 3, n=3 grade 4). The grade 4 AEs were a 
hospitalization for overweight after birth and a death just after birth due to congenital 
malformation in the control group and three still births (two fresh, one macerated) in the 
intervention group. 
 
Both platelets (p<0.001) and alanine transaminase (ALT) (p<0.001) increased significantly 
between enrolment and one week post-delivery in each randomized group, but there was no 
difference between randomized groups in any laboratory safety parameter one week post-
delivery (p>0.05). In total, 29 laboratory AEs were reported: n=14 in the control group versus 
n=15 in the intervention group (p=1.0; exact). Most were grade 1 (n=11 in each group), four 
(n=2 in each group) grade 2, one grade 3 (intervention) and two were grade 4 (haemoglobin 
<6.5 g/dL; one in each group). Eight clinical AEs were reported: three in the control group 
(n=1 grade 2, n=1 grade 3, n=1 grade 4 (an emergency C/S)) and five in the intervention 
group (n=1 grade 1, n=3 grade 2, n=1 grade 3). None of the laboratory and clinical AEs in the 
mothers or infants were judged possibly/probably related to study medication. 
 
Discussion 
Here we demonstrate that adding a seven-day course of phenytoin, as enzyme inducer, from 
labour onset produces a large and significant reduction in the elimination half-life of 
nevirapine in HIV-infected, pregnant women using single-dose nevirapine as part of pMTCT 
ARV prophylaxis. Seven days phenytoin was safe and effective with no new nevirapine 
resistance mutations observed.  
 
Importantly, nevirapine plasma concentrations at delivery were similar in those receiving and 
not receiving phenytoin, and also compared with previous studies,5, 11 similarly to our 
previous study evaluating a single-dose of carbamazepine as enzyme inducer.12 The time lag 
in enzyme inducer effect 
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 reflects the time required for transcription of CYP enzymes and protein synthesis. The delay 
in enzyme induction and the knowledge that phenytoin minimally penetrates into breast milk 
therefore ensures the protective perinatal effect of single-dose nevirapine is maintained. The 
absence of HIV-transmission during the postpartum period, similar or even lower than rates 
in previous studies,8 confirms also the efficacy of the pMTCT regime. 
 
Post-delivery, nevirapine pharmacokinetic parameters were substantially affected by enzyme 
induction. Adding phenytoin to single-dose nevirapine reduced nevirapine plasma levels by 
85% and produced a significantly larger proportion of women with undetectable nevirapine 
levels one and two weeks post-delivery. Both effects are a consequence of the 60% 
reduction in the nevirapine elimination half-life, an absolute difference of -35.8 hours. This is 
the largest decline in nevirapine elimination half-life ever reported, especially in the target 
population of HIV-infected, pregnant women. For example, the pilot study of L’homme et al 
found a median elimination half-life reduction of 38% (-19.4 hours) in four healthy, Dutch 
women receiving single-dose nevirapine with seven days phenytoin,11 and a single-dose of 
carbamazepine reduced nevirapine levels by 36% in HIV-infected, pregnant women receiving 
single-dose nevirapine.12 Not surprisingly, a seven-day course of an enzyme inducer has a 
greater effect than a single-dose alone on the elimination half-life of nevirapine in HIV-
infected, pregnant women. 
 
The mechanisms by which the CYP enzymes are induced involves the transcription factors 
pregnane X receptor and the constitutive androstane receptor. The enzyme inducer binds to 
these receptors, thereby stimulating the activation of the CYP enzyme.17 Studies have shown 
that CYP enzyme induction is correlated with dose and drug level 18 with higher doses and a 
higher plasma level of the enzyme inducer resulting in lower serum levels of the test drug. 
This likely explains why induction of the CYP enzyme has a greater effect with a long-course 
of an enzyme inducer than only the single-dose used in our previous study. 
 
Although current guidelines, including zidovudine monotherapy pre-delivery and seven days 
zidovudine/lamivudine post-delivery are complex, they have reduced emergence of 
nevirapine resistance substantially by protecting the subtherapeutic nevirapine ‘tail’, since the 
lengthy duration of low and subtherapeutic levels of nevirapine in blood are plausibly 
associated with increases in nevirapine resistance. A meta-analysis estimated that 4.5% of 
women using single-dose nevirapine and additional ARVs postpartum had nevirapine 
resistance 4-8 weeks post-partum.4 In our study, overall new nevirapine resistance 
prevalence was 2.4% (1 out of 41 samples); although we observed no nevirapine resistance 
mutations after single-dose nevirapine in combination with seven days phenytoin, clearly 
numbers are too few to make any conclusions about nevirapine resistance on the basis of 
this study alone. However, it raises the prospect that full elimination of nevirapine resistance 
could be possible. In the VITA-1 trial we found that women with undetectable nevirapine 
plasma concentrations one week post-delivery were less likely to develop nevirapine 
resistance mutations, and that the elimination half-life in women with new nevirapine 
mutation(s) was almost two and five times longer than the median half-lives in the control and 
intervention groups, respectively. Thus it is plausible that adding a seven-day course of 
phenytoin at labour onset might have significant additional benefits in reducing selection of 
nevirapine resistance mutations, even on top of the current ARV prophylaxis “tail”. 
 
The trial was designed as a pilot powered to detect a difference between intervention and 
control groups in the nevirapine elimination half-life. A much larger sample size (~200; 100 
per arm) would be needed to detect significant differences in the development of nevirapine 
resistance between the two groups. However, this group of women is extremely challenging 
to recruit and retain (Figure 1): only 23% of those assessed for eligibility pre-delivery were 
randomized, a further 26% of those randomized dropped out before delivery, and a further 
23% of those who delivered in the study clinic did not provide samples 4-6 weeks post-
delivery. We would therefore have needed to screen ~1,600 women to achieve 200 women 
with weeks 4-6 samples. Whilst ideally a larger phase III trial should confirm the efficacy of 7-
days phenytoin on resistance as a primary outcome, the substantial significant reductions in 
nevirapine half-life, coupled with previous data demonstrating a trend towards a causal 
association between nevirapine half-life and emergence of resistance, suggests it is highly 
likely to be effective. Another limitation was the standard HIV genotyping assay used which 
only detects mutations present in >20% of the viral population, and not subpopulations of 
mutants. Deep sequencing of these samples is planned.  
 
It is estimated that 18-64% of the women living in Sub-Saharan Africa with HIV are receiving 
cART for pMTCT, as now recommended by WHO (Option B+). However, this means that 
thousands of women are still receiving single-dose nevirapine,19 and demonstrates the 
challenge of widespread implementation of the current guidelines. Phenytoin can be used 
safely during pregnancy and breastfeeding 20 and side-effects are expected to be infrequent 
using such a low dose for only a short period. Where it is not possible to provide cART, 
phenytoin is cheap and available in almost every clinic. Phenytoin may also be a useful 
intervention when women stop nevirapine at the end of breastfeeding within Option B+. We 
have demonstrated that implementation of this intervention would substantially and 
significantly reduce nevirapine half-life; previous data demonstrating a trend towards a causal 
relationship between nevirapine half-life and resistance emergence suggest that 
implementation would not only facilitate the reduction of nevirapine resistance, but also 
enable further increases in coverage for pregnant women in need of perinatal HIV 
prophylaxis, whilst likely retaining the benefits of single-dose nevirapine in reducing 
transmission. This strategy might therefore support the overarching goal of the technical 
consultation of the WHO to reduce the overall HIV transmission rate from pMTCT to <5% at 
the population level by the end of 2015. 
 
In summary, addition of an enzyme inducer for seven days to single-dose nevirapine for 
pMTCT greatly reduced the presence of subtherapeutic nevirapine levels by significantly 
shortening the nevirapine elimination half-life, with no new nevirapine resistance mutations 
observed. Since prolonged subtherapeutic nevirapine exposure is known to lead to 
nevirapine resistance emergence,5, 6, 12 and since phenytoin is safely and widely used in 
women,13 to minimise HIV transmission from mother-to-child, single-dose nevirapine could be 
used with phenytoin as an alternative if other ARV drugs are unavailable. 
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Table 1: Demographic characteristics of the women and infants in the VITA-2 trial 
 Control (n=28) 
Intervention (7 days 
phenytoin; n=26) 
p-value 
At enrolment    
Age (years) 27 (23-31) 27 (23-33) 0.74 
Weight (kg) 62 (55-73) 66 (56-81) 0.11 
BMI (kg/m2) 24.1 (21.7-27.9) 26.2 (23.3-30.9) 0.10 
At delivery    
Gestational age at delivery 
(weeks) 
39 (38-42) 39 (38-41) 0.78 
CD4 cell count (cells/µl) 366 (318-522) 412 (317-518) 0.76 
HIV-1 RNA (copies/ml) 2832 (1000-26518) 2420 (1542-11261) 0.99 
Birth weight (kg) 3.0 (2.7-3.2) 3.0 (2.7-3.4) 0.87 
Time from nevirapine  
ingestion to delivery (hours) 
9.1 (2.5-12.6) 2.1 (1.0-4.9) 0.003 
 
Data are presented as median (IQR) and were tested with Rank-sum.  
Table 2: Maternal nevirapine plasma concentrations at delivery, week 1 and week 2 of women in the VITA-2 trial, including women who 
delivered by C/S. 
 
  Women who delivered, including women who delivered by C/S  
  Control Intervention p-value GMR (90% CI) 
At delivery        
Samples taken (n) 20 22     
nevirapine plasma conc. (mg/L; GM (95% CI)) 1.02 (0.58-1.78) 1.14 (0.70-1.86) 0.76 † 1.12 (0.61-2.03) 
<0.05 mg/L nevirapine (n (%)) 1 (5%) 1 (5%)     
1 week after delivery        
Samples taken (n) 23 22    
nevirapine plasma conc. (mg/L; GM (95% CI)) 0.23 (0.18 - 0.31) 0.035 (0.027-0.046) <0.001†   0.15 (0.11-0.20) 
<0.05 mg/L nevirapine (n(%)) 0 (0%) 15 (68%) <0.001*    
Women with 1 week and delivery samples (n)  20 22    
nevirapine plasma concentration  
1 week : delivery  (GMR (90% CI)) 
0.22 (0.18-0.28) 0.031 (0.026-0.038)    
2 weeks after delivery         
Samples taken (n) 21 19     
nevirapine plasma conc. (mg/L; GM (95% CI)) 0.044 (0.031-0.062) 0.026 (0.024-0.029) 0.006†   0.59 (0.44-0.80) 
<0.05 mg/L nevirapine (n(%)) 10 (48%) 18 (95%) 0.002*   
Women with week 2 and delivery samples  (n) 18 18     
nevirapine plasma conc  
2 weeks : delivery  (GMR (90% CI)) 
0.030 (0.026 - 0.034) 0.022 (0.015 - 0.031)     
 
† T-test, * Exact test. 
Median nevirapine plasma concentrations are similar to GM and are therefore not shown in Table 2.  
Figure legends 
 
Figure 1: Profile of the VITA-2 trial 
Figure 2: Geometric mean nevirapine plasma concentrations over time post-delivery (all 
women who delivered including those who delivered by C/S) 
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